11.06.19
Aptar CSP Technologies, a material science and active packaging solutions provider, has launched a complete solution service offering focusing on de-risking development and increasing speed-to-market. The new Xcelerate Development Services aim to optimize the active packaging development process with expert insight.
Xcelerate combines Aptar CSP Technologies’ material science and active packaging solution and associated services with FreeThink Technologies’ accelerated predictive modeling in shelf-life determination. Utilizing FreeThink’s ASAPprime technology, an optimized active packaging solution product is modeled and tested without the need for line trials. The result is an approach that helps eliminate repetitive design processes and reformulations caused by stability test failures.
Aptar CSP Technologies offers a portfolio of services (research and development, clinical and stability studies, commercial planning and production, etc.) built around its 3-Phase Activ-Polymer technology platform, which is delivered in a variety of configurations: Activ-Blister solutions control the internal atmosphere of individual blister cavities. Activ-Seal closures incorporate moisture and gas scavenging technology press-fit into an induction-sealed, tamper-evident screw cap. Activ-Vial portfolio consists of one-piece, flip-top desiccated vials and desiccated bottles across a range of sizes. Activ-Film was developed to enhance transdermal drug delivery systems (TDDS), which provide controlled delivery of active substances through the skin.
Xcelerate reduces the active packaging design, testing and implementation process. The comprehensive, hands-on approach also includes capabilities to produce clinical trial and stability samples, regulatory support, consulting and testing during commercial implementation.
Xcelerate’s customized process determines a drug product’s moisture and oxygen sensitivity using highly accelerated stability studies open to specified environmental conditions such as temperature, relative humidity and oxygen level, then uses modeling to create theoretical package designs. Once the optimal packaging sorbent levels are determined, laboratory, clinical and stability study sample supplies can be prepared for confirmation or actual use.
“Our complete solution of material science driven active packaging solutions, and the newly launched Xcelerate Development Services offer improved stability, extended shelf-life and expedited time-to-market for sensitive medicines,” said Craig Voellmicke, Vice President, Business Development, Aptar CSP Technologies. “Together, they provide a valuable combination of effective drug protection and ease of adoption.”
Xcelerate combines Aptar CSP Technologies’ material science and active packaging solution and associated services with FreeThink Technologies’ accelerated predictive modeling in shelf-life determination. Utilizing FreeThink’s ASAPprime technology, an optimized active packaging solution product is modeled and tested without the need for line trials. The result is an approach that helps eliminate repetitive design processes and reformulations caused by stability test failures.
Aptar CSP Technologies offers a portfolio of services (research and development, clinical and stability studies, commercial planning and production, etc.) built around its 3-Phase Activ-Polymer technology platform, which is delivered in a variety of configurations: Activ-Blister solutions control the internal atmosphere of individual blister cavities. Activ-Seal closures incorporate moisture and gas scavenging technology press-fit into an induction-sealed, tamper-evident screw cap. Activ-Vial portfolio consists of one-piece, flip-top desiccated vials and desiccated bottles across a range of sizes. Activ-Film was developed to enhance transdermal drug delivery systems (TDDS), which provide controlled delivery of active substances through the skin.
Xcelerate reduces the active packaging design, testing and implementation process. The comprehensive, hands-on approach also includes capabilities to produce clinical trial and stability samples, regulatory support, consulting and testing during commercial implementation.
Xcelerate’s customized process determines a drug product’s moisture and oxygen sensitivity using highly accelerated stability studies open to specified environmental conditions such as temperature, relative humidity and oxygen level, then uses modeling to create theoretical package designs. Once the optimal packaging sorbent levels are determined, laboratory, clinical and stability study sample supplies can be prepared for confirmation or actual use.
“Our complete solution of material science driven active packaging solutions, and the newly launched Xcelerate Development Services offer improved stability, extended shelf-life and expedited time-to-market for sensitive medicines,” said Craig Voellmicke, Vice President, Business Development, Aptar CSP Technologies. “Together, they provide a valuable combination of effective drug protection and ease of adoption.”
